INT19617

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1990
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 12
Disease Relevance 3.68
Pain Relevance 1.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (CD86) cell-cell signaling (CD86)
Anatomy Link Frequency
CD86 5
plasma 2
PDL-1 1
B cells 1
memory B-cells 1
CD86 (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 86 99.08 Very High Very High Very High
rheumatoid arthritis 71 95.68 Very High Very High Very High
psoriasis 73 93.72 High High
local anesthetic 3 93.60 High High
Inflammation 119 80.68 Quite High
Arthritis 17 63.20 Quite High
cytokine 69 61.84 Quite High
chemokine 13 56.48 Quite High
methotrexate 5 20.24 Low Low
Infliximab 15 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Anaerobic Bacterial Infections 32 99.48 Very High Very High Very High
Adhesions 16 98.72 Very High Very High Very High
Rheumatoid Arthritis 71 95.68 Very High Very High Very High
Infection 98 94.40 High High
Organ Transplantation 1 93.76 High High
Poisoning 1 93.76 High High
Psoriasis 81 93.72 High High
Graft Vs Host Disease 2 91.92 High High
Photosensitivity Disorders 9 86.24 High High
Phototoxic Dermatitis 12 85.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Following a 48 h incubation, the expression of the cell surface molecules CD86, HLA-DR and CD83 was measured by flow cytometry.
Negative_regulation (measured) of CD86 in CD86
1) Confidence 0.42 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC3009729 Disease Relevance 0.40 Pain Relevance 0
Marked T cell proliferation in the coculture was completely abrogated by mAb blockade of CD86, confirming that costimulatory properties are conferred on ECs by CD86 expression.
Negative_regulation (blockade) of CD86 in CD86
2) Confidence 0.42 Published 2008 Journal J. Immunol. Section Abstract Doc Link 18941200 Disease Relevance 0.54 Pain Relevance 0.14
The inhibition of the CD80/CD86:CD28 co-stimulatory signal may also potentially prevent the T-cell 'help' needed for optimal differentiation of CD80/CD86-expressing B cells into plasma cells, which ultimately secrete antibodies.
Negative_regulation (inhibition) of CD86 in B cells
3) Confidence 0.41 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1906816 Disease Relevance 0.17 Pain Relevance 0.55
By D14 p.i., the percentage of CD80+ cells had decreased by a factor of 1.5, CD86+ had decreased by a factor of 1.2 and total memory B-cells by a factor of 1.3.
Negative_regulation (+ had dec) of CD86 in memory B-cells
4) Confidence 0.25 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2695011 Disease Relevance 0.19 Pain Relevance 0
Abatacept is a recombinant soluble fusion protein that inhibits the CD80/CD86:CD28 costimulatory signal required for T cell activation and has demonstrated efficacy in the treatment of rheumatoid arthritis.
Negative_regulation (inhibits) of CD86 in T cell associated with rheumatoid arthritis and abatacept
5) Confidence 0.25 Published 2007 Journal J Clin Pharmacol Section Abstract Doc Link 17962428 Disease Relevance 0.33 Pain Relevance 0.39
In contrast, a preferential and sustained depletion of SIgG-, CD86-, CD95-expressing memory B-cells was observed in LN and spleen.


Negative_regulation (depletion) of CD86 in CD86
6) Confidence 0.25 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2695011 Disease Relevance 0.41 Pain Relevance 0
In addition, the LC also acquires a number of cell surface receptor markers such as CD80, CD86, CD40, CD83, and intercellular adhesion molecule (ICAM) 1.
Negative_regulation (number) of CD86 in CD86 associated with adhesions
7) Confidence 0.21 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.42 Pain Relevance 0.15
Inhibition of CD28-mediated co-stimulatory signals is a potent means of immunosuppression that can be achieved by blocking either CD28 or CD80 and CD86.
Negative_regulation (blocking) of CD86 in CD86
8) Confidence 0.18 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833981 Disease Relevance 0.83 Pain Relevance 0.27
Five minutes after the intravenous injection, iohexol reduces BuChE plasma activity by 8.5% but this effect disappears within 15 minutes.
Negative_regulation (reduces) of BuChE in plasma
9) Confidence 0.11 Published 1998 Journal Invest Radiol Section Abstract Doc Link 9609490 Disease Relevance 0 Pain Relevance 0.09
Diatrizoate and iopentol decrease BuChE plasma activity by 8% and 15.2%, respectively, 5 minutes after the injection and this effect remains stable for the next 15 minutes.
Negative_regulation (decrease) of BuChE in plasma
10) Confidence 0.11 Published 1998 Journal Invest Radiol Section Abstract Doc Link 9609490 Disease Relevance 0 Pain Relevance 0.09
The TLR3 ligation induced a MDC maturation profile with upregulation of the markers; CD40, CD83, CD86, CCR7, PDL-1, and downregulation of ICOSL, B7H3, and CCR5 (Figure 9).
Negative_regulation (downregulation) of CD86 in PDL-1
11) Confidence 0.08 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955544 Disease Relevance 0.30 Pain Relevance 0.03
The presence of the Gly-70 mutation alone was found to render the enzyme resistant to 100 microM solanidine and 5 mM succinylcholine; concentrations sufficient to inhibit the "normal," Asp-70 containing BuChE by over 50%.
Negative_regulation (inhibit) of BuChE
12) Confidence 0.00 Published 1990 Journal J. Neurosci. Res. Section Abstract Doc Link 2079709 Disease Relevance 0.09 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox